At the molecular level, combination therapy dramatically increased the number of MART1-specific CD8+ T cells in the tumor and frequency of memory precursor CD62L+/CD45RO+/ CCR7+CD8+ T cells in the spleen, which coincided with enhanced IFN-γ production by tumor antigen-specific CD8+ T cells. Here, CD8A is linked to neoplasm.